| Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire) Genomic Health, Inc. today announced the results of six studies being presented at the American Society of Clinical Oncology Annual Meeting, including an evaluation of biological similarities and differences between stage II and III colon cancer, suggesting a potential role for the Oncotype DX® colon cancer test in patients with stage III disease, pending further study. us.rd.yahoo.com |
Humana's Net Jumps 21% Humana said profit jumped 21% on improved revenue as membership increased. The managed-care provider raised its 2010 earnings target again. online.wsj.com |
Enzon Pharma: R&D Spending Will Eventually Pay Off Gaurav Sharma submits:Value investors normally shy away from pharmaceutical companies. These companies tend to gobble up lots of cash to produce drugs whose approval odds are worse than a coin toss. But where there is less crowd, there is more opportunity. A strategy that my favorite investor, Seth Klarman, follows is to buy into companies which already have substantial long term royalty incomes protected by their patents but are burning cash because of management spending it on expensive R&D efforts.One such company is ENZON Pharma (ENZN), which has been completely revitalized by the activist shareholder. Here is a case study of this company as it stands today.Complete Story » seekingalpha.com |
Enzo Biochem 4Q loss widens on costs [AP] - Biotechnology company Enzo Biochem Inc. said Thursday that its fourth-quarter loss widened as it accounted for restructuring costs. us.rd.yahoo.com |
Let’s make all kids lead-free kids - Video National Campaign Launches to Protect Children and Families from Lead Poisoning feedproxy.google.com |